CASI Pharmaceuticals (CASIF) Total Non-Current Liabilities (2021 - 2025)

CASI Pharmaceuticals has reported Total Non-Current Liabilities for 5 years, with the latest figure at $49.7 million in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities rose 36.26% year-over-year to $49.7 million; the trailing twelve-month figure through Dec 2025 stood at $49.7 million (up 36.26% YoY), and the FY2025 full-year result was $49.7 million, up 36.26% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $49.7 million, up from $39.4 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $49.7 million in Q4 2025, with the low at -$15.4 billion in Q4 2023.
• Historically, Total Non-Current Liabilities has averaged -$5.2 billion across 5 years, with a median of $17.0 million in 2022.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities slumped 90843.29% — and 2025, when it soared 100.27%.
• CASI Pharmaceuticals' Total Non-Current Liabilities stood at $16.0 million in 2021, then climbed by 6.19% to $17.0 million in 2022, then tumbled by 90843.29% to -$15.4 billion in 2023, then soared by 100.24% to $36.5 million in 2024, then soared by 36.26% to $49.7 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $49.7 million (Q4 2025), $39.4 million (Q3 2025), and $37.7 million (Q2 2025), per Business Quant data.